Company CStone Pharmaceuticals

Equities

2616

KYG2588M1006

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for CStone Pharmaceuticals

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Hong Kong S.E. Other stock markets 04:09:13 2024-04-23 am EDT			5-day change	1st Jan Change
0.86 ^HKD	0.00%		0.00%	-62.11%

Apr. 09	China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor	MT
Apr. 09	CStone Announces the Availability of RET Inhibitor GAVRETO® Manufacturing Localization Application by Center for Drug Evalence of China NMPA	CI

CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market.

Number of employees: 474

Managers	Title	Age	Since
Jian Xin Yang CEO	Chief Executive Officer	60	16-11-30
Jun Cheng DFI	Director of Finance/CFO	44	22-02-28
Ying Hua Zhang COO	Chief Operating Officer	44	16-07-31
Wei Cong Ni SEC	Corporate Secretary	-	18-07-31
Sanhu Wang LAW	General Counsel	53	19-05-31
Shirley Zhao PRN	Corporate Officer/Principal	-	19-12-05
Michael J. Choi PRN	Corporate Officer/Principal	53	21-04-30
Yin Kwan Ho SEC	Corporate Secretary	47	22-07-27

Members of the board	Title	Age	Since
Edward Hu BRD	Director/Board Member	61	21-07-08
Wei Li BRD	Director/Board Member	52	18-09-30
Ting Yuk Wu BRD	Director/Board Member	69	19-02-13
Hong Bin Sun BRD	Director/Board Member	48	19-02-13
Paul Herbert Chew BRD	Director/Board Member	72	19-02-13
Xiang Hong Lin BRD	Director/Board Member	53	20-11-29
Jian Xin Yang CEO	Chief Executive Officer	60	16-11-30
Kenneth Hitchner BRD	Director/Board Member	63	21-12-09

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,284,191,212	676,090,722 ( 52.65 %)	0	52.65 %

Name	Equities	%	Valuation
6 Dimensions Capital 22.85 %	293,381,444	22.85 %	35 M $
Suzhou Oriza Holdings Co. Ltd. 5.883 %	75,553,730	5.883 %	9 M $
GIC Special Investments Pte Ltd. 4.627 %	59,422,472	4.627 %	7 M $
Ning Jun Jiang 1.016 %	13,048,250	1.016 %	2 M $
Jian Xin Yang 0.9548 %	12,260,756	0.9548 %	1 M $
Bosera Asset Management Co., Ltd. 0.7215 %	9,265,500	0.7215 %	1 M $
Kenneth Hitchner 0.2375 %	3,049,930	0.2375 %	366 327 $
Amundi Ireland Ltd. (United Kingdom) 0.0609 %	782,500	0.0609 %	93 986 $
Xinyuan Asset Management Co., Ltd. 0.0580 %	745,000	0.0580 %	89 482 $
China Asset Management (Hong Kong) Ltd. 0.005607 %	72,000	0.005607 %	8 648 $

CStone Pharmaceuticals Co. Ltd.

North Block Suzhou Industrial Park 218 Xinghu Street

200126, Shanghai

+86 512 8718 6550

http://www.cstonepharma.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7951 CNY

Average target price

3.186 CNY

Spread / Average Target

+300.76%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CSTONE PHARMACEUTICALS	-62.11%	135M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	103B
REGENERON PHARMACEUTICALS, INC.	+3.31%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.16%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-22.87%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.98B

Bio Therapeutic Drugs